Skip to main content
Erschienen in: Pediatric Drugs 2/2012

01.04.2012 | Review Article

Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents

verfasst von: Dr Steffani R. Bailey, Erin E. Crew, Emily C. Riske, Seth Ammerman, Thomas N. Robinson, Joel D. Killen

Erschienen in: Pediatric Drugs | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Adolescent smoking remains a public health problem. Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers. This is particularly true regarding pharmacologic treatments for nicotine dependence. Currently, pharmacologic aids are not recommended for treating adolescent nicotine dependence, as efficacy has not been shown in this population.
This review includes studies that have examined the efficacy of pharmacotherapy for smoking abstinence and/or reduction in cigarette consumption among adolescent smokers who want to quit smoking, laboratory-based adolescent studies that have examined the efficacy of these medications in reducing cravings and/or withdrawal symptoms, and/or studies that have assessed the tolerability of medications for smoking cessation in adolescent smokers. It provides information on the pharmacologic action of each medication, the efficacy of each medication for adolescent smoking cessation, the tolerability of each medication based on reported adverse events, and compliance with the medication protocols.
Thirteen relevant articles were identified and included in the review. Nicotine patch (NP), nicotine gum, nicotine nasal spray, bupropion, and varenicline have been studied in adolescent smokers. The adverse events reported in the studies on pharmacology for adolescent smoking suggest that the side effect profiles for nicotine replacement therapy, bupropion, and varenicline are similar to those reported in adult studies. There is some evidence of efficacy of NP and bupropion at the end of treatment (efficacy of varenicline has not been assessed), but none of the medications included in this review were efficacious in promoting long-term smoking cessation among adolescent smokers. It is noted that many of the study protocols did not follow the recommended dose or length of pharmacotherapy for adults, rendering it difficult to determine the true efficacy of medication for adolescent smoking cessation. Future efficacy studies are warranted before recommending pharmacotherapy for adolescent smoking cessation.
Literatur
1.
2.
Zurück zum Zitat Substance Abuse and Mental Health Service Administration, Office of Applied Studies. The NSDUH report. Trends in substance use, dependence or abuse, and treatment among adolescents: 2002–2007. Rockville (MD): Substance Abuse and Mental Health Service Administration, 2008 Dec 4 Substance Abuse and Mental Health Service Administration, Office of Applied Studies. The NSDUH report. Trends in substance use, dependence or abuse, and treatment among adolescents: 2002–2007. Rockville (MD): Substance Abuse and Mental Health Service Administration, 2008 Dec 4
3.
Zurück zum Zitat Johnston LD, O’Malley PM, Bachman JG, et al. Monitoring the Future national results on adolescent drug use: overview of key findings, 2009. NIH publication no. 10-7583. Bethesda (MD): National Institute on Drug Abuse, 2010 Johnston LD, O’Malley PM, Bachman JG, et al. Monitoring the Future national results on adolescent drug use: overview of key findings, 2009. NIH publication no. 10-7583. Bethesda (MD): National Institute on Drug Abuse, 2010
4.
Zurück zum Zitat Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General (DHHS publication no. CDC 89-8411). Washington, DC: U.S. Government Printing Office, 1994 Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General (DHHS publication no. CDC 89-8411). Washington, DC: U.S. Government Printing Office, 1994
5.
Zurück zum Zitat Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville (MD): U.S. Department of Health and Human Services, 2008 May Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville (MD): U.S. Department of Health and Human Services, 2008 May
6.
Zurück zum Zitat Bailey SR, Harrison CT, Jeffery CJ, et al. Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? Addict Behav 2009; 34(12): 1017–22PubMedCrossRef Bailey SR, Harrison CT, Jeffery CJ, et al. Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? Addict Behav 2009; 34(12): 1017–22PubMedCrossRef
7.
Zurück zum Zitat Killen JD, Ammerman S, Rojas N, et al. Do adolescent smokers experience withdrawal effects when deprived of nicotine? Exp Clin Psychopharmacol 2001; 9(2): 176–82PubMedCrossRef Killen JD, Ammerman S, Rojas N, et al. Do adolescent smokers experience withdrawal effects when deprived of nicotine? Exp Clin Psychopharmacol 2001; 9(2): 176–82PubMedCrossRef
8.
Zurück zum Zitat Colby SM, Tiffany ST, Shiffman S, et al. Are adolescent smokers dependent on nicotine? A review of the evidence. Drug Alcohol Depend 2000; 59Suppl. 1: S83–95PubMedCrossRef Colby SM, Tiffany ST, Shiffman S, et al. Are adolescent smokers dependent on nicotine? A review of the evidence. Drug Alcohol Depend 2000; 59Suppl. 1: S83–95PubMedCrossRef
9.
Zurück zum Zitat Rojas NL, Killen JD, Haydel KF, et al. Nicotine dependence among adolescent smokers. Arch Pediatr Adolesc Med 1998; 152(2): 151–6PubMedCrossRef Rojas NL, Killen JD, Haydel KF, et al. Nicotine dependence among adolescent smokers. Arch Pediatr Adolesc Med 1998; 152(2): 151–6PubMedCrossRef
10.
Zurück zum Zitat Hanson K, Zylla E, Allen S, et al. Cigarette reduction: an intervention for adolescent smokers. Drug Alcohol Depend 2008; 95(1-2): 164–8PubMedCrossRef Hanson K, Zylla E, Allen S, et al. Cigarette reduction: an intervention for adolescent smokers. Drug Alcohol Depend 2008; 95(1-2): 164–8PubMedCrossRef
11.
Zurück zum Zitat Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7PubMedCrossRef Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7PubMedCrossRef
12.
Zurück zum Zitat Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146 Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146
13.
Zurück zum Zitat Hudmon KS, Corelli RL, Prokhorov AV. Current approaches to pharma-cotherapy for smoking cessation. Ther Adv Respir Dis 2010; 4(1): 35–47PubMedCrossRef Hudmon KS, Corelli RL, Prokhorov AV. Current approaches to pharma-cotherapy for smoking cessation. Ther Adv Respir Dis 2010; 4(1): 35–47PubMedCrossRef
14.
Zurück zum Zitat Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98(4): 659–67PubMed Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98(4): 659–67PubMed
15.
Zurück zum Zitat Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000; 154(1): 31–7PubMed Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000; 154(1): 31–7PubMed
16.
Zurück zum Zitat Hanson K, Allen S, Jensen S, et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003; 5(4): 515–26PubMed Hanson K, Allen S, Jensen S, et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003; 5(4): 515–26PubMed
17.
Zurück zum Zitat Roddy E, Romilly N, Challenger A, et al. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. Tob Control 2006; 15: 373–6PubMedCrossRef Roddy E, Romilly N, Challenger A, et al. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. Tob Control 2006; 15: 373–6PubMedCrossRef
18.
Zurück zum Zitat Moolchan ET, Robinson ML, Ernst M, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005; 115(4): e407–14PubMedCrossRef Moolchan ET, Robinson ML, Ernst M, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005; 115(4): e407–14PubMedCrossRef
19.
Zurück zum Zitat Rubinstein ML, Benowitz NL, Auerback GM, et al. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics 2008; 122(3): e595–600PubMedCrossRef Rubinstein ML, Benowitz NL, Auerback GM, et al. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics 2008; 122(3): e595–600PubMedCrossRef
20.
Zurück zum Zitat Upadhyaya HP, Brady KT, Wang W. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 2004; 43(2): 199–205PubMedCrossRef Upadhyaya HP, Brady KT, Wang W. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 2004; 43(2): 199–205PubMedCrossRef
21.
Zurück zum Zitat Niederhofer H, Huber M. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. Pharmacotherapy 2004; 24(11): 1524–8PubMedCrossRef Niederhofer H, Huber M. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. Pharmacotherapy 2004; 24(11): 1524–8PubMedCrossRef
22.
Zurück zum Zitat Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72(4): 729–35PubMedCrossRef Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72(4): 729–35PubMedCrossRef
23.
Zurück zum Zitat Muramoto ML, Leischow SJ, Sherrill D, et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 2007; 161(11): 1068–74PubMedCrossRef Muramoto ML, Leischow SJ, Sherrill D, et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 2007; 161(11): 1068–74PubMedCrossRef
24.
Zurück zum Zitat Gray KM, Carpenter MJ, Baker NL, et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat 2011; 40(1): 77–86PubMedCrossRef Gray KM, Carpenter MJ, Baker NL, et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat 2011; 40(1): 77–86PubMedCrossRef
25.
Zurück zum Zitat CHANTIX® (varenicline) tablets: US prescribing information. New York: Pfizer Labs, 2010 CHANTIX® (varenicline) tablets: US prescribing information. New York: Pfizer Labs, 2010
26.
Zurück zum Zitat Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8(8): 1–15 Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8(8): 1–15
27.
Zurück zum Zitat Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31(1): 177–89PubMedCrossRef Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31(1): 177–89PubMedCrossRef
28.
Zurück zum Zitat Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicol Teratol 2002; 24(3): 369–84PubMedCrossRef Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicol Teratol 2002; 24(3): 369–84PubMedCrossRef
29.
Zurück zum Zitat Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol 2008; 30(1): 1–19PubMedCrossRef Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol 2008; 30(1): 1–19PubMedCrossRef
30.
Zurück zum Zitat Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295(1): 321–7PubMed Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295(1): 321–7PubMed
31.
Zurück zum Zitat ZYBAN® (bupropion hydrochloride) sustained-released tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2010 ZYBAN® (bupropion hydrochloride) sustained-released tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2010
32.
Zurück zum Zitat Ossip-Klein DJ, Bigelow G, Curry S, et al. Task force 1: classification and assessment of smoking behavior. Health Psychol 1986; 5 Suppl.: 3–11PubMedCrossRef Ossip-Klein DJ, Bigelow G, Curry S, et al. Task force 1: classification and assessment of smoking behavior. Health Psychol 1986; 5 Suppl.: 3–11PubMedCrossRef
33.
Zurück zum Zitat Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031
34.
Zurück zum Zitat Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337(17): 1195–202PubMedCrossRef Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337(17): 1195–202PubMedCrossRef
35.
Zurück zum Zitat Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163(19): 2337–44PubMedCrossRef Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163(19): 2337–44PubMedCrossRef
36.
Zurück zum Zitat Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog in Neuropsychopharmacol Biol Psychiatry 2005; 29(5): 819–26CrossRef Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog in Neuropsychopharmacol Biol Psychiatry 2005; 29(5): 819–26CrossRef
37.
Zurück zum Zitat Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52(3): 985–94PubMedCrossRef Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52(3): 985–94PubMedCrossRef
38.
Zurück zum Zitat Sussman S, Sun P, Dent CW. A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006; 25(5): 549–57PubMedCrossRef Sussman S, Sun P, Dent CW. A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006; 25(5): 549–57PubMedCrossRef
Metadaten
Titel
Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents
verfasst von
Dr Steffani R. Bailey
Erin E. Crew
Emily C. Riske
Seth Ammerman
Thomas N. Robinson
Joel D. Killen
Publikationsdatum
01.04.2012
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 2/2012
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11594370-000000000-00000

Weitere Artikel der Ausgabe 2/2012

Pediatric Drugs 2/2012 Zur Ausgabe

Adis Drug Profile

Atazanavir

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.